The effects of rivaroxaban, an oral anticoagulant, on human IVD primary cultures

Abstract

IntroductionThe present study aimed to investigate the potential effects of rivaroxaban, an oral anticoagulant that inhibits the effects of factor Xa on intact intervertebral disc tissue cells and the extracellular matrix (ECM).Material and methodsRivaroxaban was applied to primary human cell cultures prepared from tissues of the intervertebral disc. Comparative molecular analyses were performed on non-drug-treated control group samples. Descriptive statistics were presented as the mean ± standard deviation. An analysis of variance (ANOVA) test was performed to determine whether there were significant differences in the mean across the groups. When differences across groups were observed, Tukey’s honestly significant difference (HSD) post-hoc test was used for multiple pairwise comparisons. The significance of the obtained data was determined statistically. The alpha (P) significance value was < 0.05.ResultsThe cells in the control group and in the rivaroxaban-treated group were viable, healthy, and proliferated (P < 0.05). However, the expressions of the chondroadherin gene (CHAD), cartilage oligo matrix protein (COMP), matrix metallo proteinase (MMP)-13, and MMP-19 genes were changed (P < 0.05).ConclusionsAlthough rivaroxaban does not suppress cell proliferation due to morphological, biological, and biochemical changes in the intervertebral disc tissue, it may change the expression of genes that are related to ECM maintenance.

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study

“…It is associated with anticoagulants and haemorrhage. In primary human cell cultures, administration of rivaroxaban increased MMP‐13 with a 36.3‐fold change ( p < .05) 35 . In atherosclerotic lesions, activation of MMP‐13 was associated to aggravate collagen breakdown and intra‐plaque haemorrhages 36 .…”

“…In primary human cell cultures, administration of rivaroxaban increased MMP-13 with a 36.3-fold change (p < .05). 35 In atherosclerotic lesions, activation of MMP-13 was associated to aggravate collagen breakdown and intra-plaque haemorrhages. 36 In the present study, compared with TT wild homozygous, GG genotype of MMP13 rs640198 increased peak anti-FXa level by 16.8% and the incidence of bleeding events within 12 months by 1.53-fold change.…”